NeoGenomics (NASDAQ:NEO) had its price objective boosted by Raymond James from $16.00 to $21.00 in a report published on Wednesday. The firm currently has a buy rating on the medical research company’s stock. Other equities research analysts have also issued reports about the company. BidaskClub lowered NeoGenomics from a strong-buy rating to a buy rating […]


Full article